Figueiredo-Pontes LL - Search Results

1

[From the molecular model to the impact on prognosis: an overview on acute promyelocytic leukemia].

Jácomo RH, Figueiredo-Pontes LL, Rego EM. Jácomo RH, et al. Rev Assoc Med Bras (1992). 2008 Jan-Feb;54(1):82-9. doi: 10.1590/s0104-42302008000100026. Rev Assoc Med Bras (1992). 2008. PMID: 18392492 Free article. Review. Portuguese.

2

Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax.

Lima K, Vicari HP, Carlos JAEG, da Silva JCL, Figueiredo-Pontes LL, Rego EM, Machado-Neto JA. Lima K, et al. Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):124-127. doi: 10.1016/j.htct.2021.01.004. Epub 2021 Mar 13. Hematol Transfus Cell Ther. 2022. PMID: 33753045 Free PMC article. No abstract available.

3

Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.

Borges CS, Ferreira AF, Almeida VH, Gomes FG, Berzoti-Coelho MG, Cacemiro MDC, Nunes NS, Figueiredo-Pontes LL, Simões BP, Castro FA, Monteiro RQ. Borges CS, et al. Exp Hematol. 2018 Oct;66:50-62. doi: 10.1016/j.exphem.2018.07.008. Epub 2018 Aug 1. Exp Hematol. 2018. PMID: 30076949 Free article.

4

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms.

Porto-Soares MA, de Oliveira RD, Cortopassi GM, Machado-Neto JA, Palma LC, Figueiredo-Pontes LL. Porto-Soares MA, et al. Hematol Transfus Cell Ther. 2020 Jul-Sep;42(3):238-244. doi: 10.1016/j.htct.2019.07.008. Epub 2019 Oct 10. Hematol Transfus Cell Ther. 2020. PMID: 31676277 Free PMC article.

5

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation.

Cacemiro MDC, Cominal JG, Tognon R, Nunes NS, Simões BP, Figueiredo-Pontes LL, Catto LFB, Traina F, Souto EX, Zambuzi FA, Frantz FG, Castro FA. Cacemiro MDC, et al. Hematol Transfus Cell Ther. 2018 Apr-Jun;40(2):120-131. doi: 10.1016/j.htct.2017.12.003. Epub 2018 Feb 17. Hematol Transfus Cell Ther. 2018. PMID: 30057985 Free PMC article.

6

Differential cytokine network profile in polycythemia vera and secondary polycythemia.

Cacemiro MDC, Cominal JG, Berzoti-Coelho MG, Tognon R, Nunes NS, Simões B, Pereira ÍS, Carlos D, Faccioli LH, Figueiredo-Pontes LL, Frantz FG, Castro FA. Cacemiro MDC, et al. Sci Rep. 2020 Apr 27;10(1):7032. doi: 10.1038/s41598-020-63680-7. Sci Rep. 2020. PMID: 32341381 Free PMC article.

7

Transcriptional deregulation of LSD1 and LSD2 is associated with cytogenetic risk in chronic lymphocytic leukemia.

Costa DFD, Filiú-Braga LDC, Silva-Carvalho AÉ, Schiavinato JL, Vasconcelos MCC, Figueiredo-Pontes LL, Lucena-Araujo AR, Saldanha-Araujo F. Costa DFD, et al. Among authors: figueiredo pontes ll. Leuk Lymphoma. 2022 Dec;63(13):3227-3231. doi: 10.1080/10428194.2022.2116935. Epub 2022 Aug 25. Leuk Lymphoma. 2022. PMID: 36016463 No abstract available.

8

Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy.

de Figueiredo-Pontes LL, Catto LFB, Chauffaille MLLF, Pagnano KBB, Madeira MIA, Nunes EC, Hamerschlak N, de Andrade Silva MC, Carneiro TX, Bortolheiro TC, de Freitas TT, Bittencourt RI, Maranhão Fagundes E, Magalhães Rego E. de Figueiredo-Pontes LL, et al. Hematol Transfus Cell Ther. 2024 May 18:S2531-1379(24)00253-0. doi: 10.1016/j.htct.2024.05.002. Online ahead of print. Hematol Transfus Cell Ther. 2024. PMID: 38890097 Free article.

9

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.

Koury LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, Salinas V, Muxi P, Melo RAM, Gloria ABF, Pagnano KBB, Nunes EC, Bittencourt RI, Rojas N, Quintana Truyenque SM, Ayala-Lugo AI Dr, Oliver AC, de Figueiredo-Pontes LL, Traina F, Moreira F, Fagundes EM, Duarte BKL, Mora-Alferez AP, Ortiz P, Untama JL, Tallman MS, Ribeiro RC, Ganser A, Dillon RJ, Valk PJM, Sanz MA, Löwenberg B, Berliner N, Rego EM. Koury LCA, et al. Among authors: de figueiredo pontes ll. Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890. Online ahead of print. Blood. 2024. PMID: 38805638

10

Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study.

Murbach B, Duarte G, Palma LC, Miranda E, Duffles G, Furlin GP, Toni I, De Souza C, Binelli L, Bassan VL, de Castro FA, de Figueiredo-Pontes LL, Pagnano KBB. Murbach B, et al. Among authors: de figueiredo pontes ll. Front Oncol. 2024 May 8;14:1393191. doi: 10.3389/fonc.2024.1393191. eCollection 2024. Front Oncol. 2024. PMID: 38779092 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page